Maintaining and Incrementally Revalidating a Computer-Based Clinical Guideline: A Case Study  by Miller, Perry L. et al.
Journal of Biomedical Informatics 34, 99–111 (2001)
doi:10.1006/jbin.2001.1011, available online at http://www.idealibrary.com on
Maintaining and Incrementally Revalidating a Computer-Based
Clinical Guideline: A Case Study
Perry L. Miller,*,1 Sandra J. Frawley,*,† and Frederick G. Sayward*,†
*Center for Medical Informatics, Yale University School of Medicine, New Haven, Connecticut 06520-8009;
and †Medical Decision Associates, Inc., Hamden, Connecticut
Received February 17, 2001; published online June 6, 2001
The paper explores the issues involved in maintaining the logic
within a complex computer-based clinical guideline, using as a case
study IMM/Serve, an operational guideline whose domain is childhood
immunization. For a period of more than a year and a half, we have
maintained a log of (1) the national changes to the immunization
recommendations, (2) the local customizations of IMM/Serve’s logic,
and (3) certain logic problems that arose in the process of accommodat-
ing these changes and customizations. We describe the nature of these
changes, customizations, and problems. We also discuss how different
types of domain knowledge might assist in the automated process of
validating successive versions of the logic. The paper’s goal is to use
the immunization domain to provide specific examples of the issues
and problems that arise in maintaining a computer-based clinical guide-
line. q 2001 Academic Press
1. INTRODUCTIONThere is a major national emphasis on the development
of computer-based clinical practice guidelines that produce
patient-specific recommendations. Once such a guideline
becomes operational, there is a continuing need to keep
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All rights of reproduction in any form reserved.its knowledge up-to-date as the clinical recommendations
evolve over time. It is essential that the successive versions
of the guideline be thoroughly tested in a timely fashion.
Similar needs arise when the guideline’s logic is customized
for use at different clinics and health centers. It will be
important to develop computer-based tools that can help test
and validate these incremental versions of the logic.
We are exploring these issues in the context of IMM/
Serve [1], a computer-based guideline that produces recom-
mendations for childhood immunization [2]. IMM/Serve has
been used for several years by the U.S. Indian Health Service
(IHS), the State of Alaska Public Health Service, and the
Oregon Health Division (OHD) immunization registry, and
is currently being adopted by the Commonwealth of Virginia
for use by its immunization registry. IMM/Serve currently
handles the following vaccine series: Diphtheria–tetanus–
pertussis (DTP), hepatitis A (HepA), hepatitis B (HepB),
Haemophilus influenzae type b (Hib), measles–mumps–
rubella (MMR), polio, Streptococcus pneumoniae (SPn),
and varicella (Var).IMM/Serve’s recommendations largely reflect those of
the CDC’s Advisory Committee on Immunization Practices
(ACIP). For the past several years, this committee has made
major changes in its recommendations each year. In addition,
there has been significant local customization of IMM/
Serve’s logic by its users.
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This paper uses our experience with IMM/Serve to discuss
the issues that arise in maintaining a guideline’s logic. For
a period of more than a year and a half (June 1999 to
February 2001), we have maintained a log of (1) the national
changes to the recommendations, (2) the local customiz-
ations of the logic, and (3) certain logic problems that arose
(as discussed later in the paper) in the process of accommo-
dating these changes and customizations. The paper de-
scribes the nature of these changes, customizations, and
problems, and characterizes them in several ways. It also
discusses the type of domain knowledge that is required to
test new versions of the guideline in an automated fashion.
The goal of the paper is to use the immunization domain
to provide specific examples of the issues and problems that
arise in maintaining the logic in a computer-based clinical
guideline. We believe that a detailed set of examples could
plored aspects of the maintenance of clinical knowledge,be a valuable resource for any group that is contemplating
the creation of a complex computer-based clinical guideline.
A long-term goal of the research is to develop a spectrum
of computer-based tools that can assist in the maintenance
and incremental revalidation process.
2. BACKGROUND
This section discusses several approaches that have been
taken to the representation of clinical guideline logic and to
the maintenance and validation of that logic.
Computer-Based Representation of Guideline Logic
A number of approaches have been used to represent the
knowledge contained in computer-based clinical practice
guidelines. These include the following.
1. Arden Syntax. The Arden Syntax is a procedural ap-
proach designed primarily to facilitate standardized repre-
sentation of relatively self-contained clinical alerts and
reminders [3, 4].
2. If–then rules. If–then rules have been widely used
within medicine to encode both diagnostic and treatment
logic [5].
3. Decision tables. Decision tables provide a compact
representation for the interaction between several clinical
variables that underlie clinical decisions, as long as the num-
ber of such variables is not too large [6].MILLER, FRAWLEY, AND SAYWARD
4. GLIF. Work on GLIF (Guideline Interchange For-
mat) is developing a standardized approach for expressing
guideline logic using an underlying flowchart paradigm
[7, 8].
5. More complex representations. More complex repre-
sentations include the modeling of temporal logic and the
creation of reusable decision templates [9, 10]. These more
complex representations include those used by “second gen-
eration expert systems.” One feature of such systems is that
they may include certain types of broader domain knowledge
beyond that required just to implement the logic in computer-
based form. Thus, some of the logic that we refer to later
in the paper as “external to the implementation logic” may
be encoded in such systems.
IMM/Serve uses three complementary approaches to rep-
resent its domain knowledge [1].
1. Tables: IMM/Serve uses tables to store many of its
temporal parameters. For each dose of each vaccine series,
these parameters include a minimum age and minimum wait-
interval from previous doses for different clinical conditions.
The two main tables are (a) a dose forecasting table that
currently contains 50 rows and 11 columns of temporal
parameters, and (b) a dose screening table which currently
contains 74 rows and 6 columns of temporal parameters
together with a modest amount of decision logic.
2. If–then rules: IMM/Serve contains roughly 360 if–then
rules. These include the logic that determines which set of
parameters applies to a particular patient at a particular time
and which vaccine preparation to use.
3. Procedural logic: IMM/Serve contains approximately
20,000 lines of code (roughly 400 pages) in the C program-
ming language which coordinate the system’s operation.
This includes certain domain logic that could not readily be
expressed within the tables and if–then rules.
Testing and Maintaining Clinical Decision Logic
An early project that focused on clinical knowledge vali-
dation was the development of the Oncocin rule checker,
which analyzed rule-based knowledge for redundancy and
inconsistency [11]. Several recent projects have also ex-including (1) issues involving changes over time [12], (2)
using a database to help manage the knowledge maintenance
process [13], and (3) exploring different techniques to assist
in maintaining clinical knowledge [14].
In the broader field of software engineering beyond medi-
cine, there has been work on the generation of test cases
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using domain knowledge expressed in the form of relations
and constraints derived from a semantic model of the domain
[15–17]. This work typically deals with logic, such as de-
scriptions of computer programs or manufactured devices,
whose structure is designed and therefore well-defined. One
problem in clinical medicine is that the underlying semantic
model on which clinical decisions are based is typically not
clear-cut and well-defined.
In our work in childhood immunization, we have devel-
oped several software tools to assist in knowledge mainte-
nance. IMM/Def allows the knowledge engineer to double-
check the complex “kernel” of the rule-based component
of IMM/Serve’s knowledge [18]. IMM/Test automatically
generates test cases to help validate the logic of this rule
kernel [19]. Commander explores how explicitly stated con-
straints can be imposed on the process of generating combi-
nations of input conditions that could help in the immuniza-
tion knowledge checking process [20]. T/Gen generalizes
the constraint-based approach taken by Commander to make
it domain-independent [21]. The current project builds on
this work and attempts to understand and characterize the
nature of the changes made to a knowledge base and the
types of logic problems that occur in the real world. One
goal is to understand how knowledge maintenance tools can
most effectively be designed.
3. IMM/SERVE’S KNOWLEDGE MAINTENANCE
LOG: RECOMMENDATION CHANGES, LOCAL
CUSTOMIZATIONS, AND INCREMENTAL LOGIC
PROBLEMS
To maintain IMM/Serve’s logic and functionality, the de-
velopment team is in frequent communication throughout
the year with clinical experts at the registries that use IMM/
Serve. Both groups monitor the results of ACIP meetings
and the relevant Recommendations and Reports (posted
at http://www.cdc.gov/nip/publications/ACIP-list.htm). The
goal is to have a new release of IMM/Serve available at
about the same time as the ACIP’s annual recommendations
are published in late January. Major changes, such as the
introduction of a new vaccine series, have typically been
under discussion for a year or longer. As a result, there
is usually an extended opportunity to analyze anticipated
changes and to identify any gaps or inconsistencies that need
to be resolved as the recommendations are incorporated into
IMM/Serve. Typically, IMM/Serve’s knowledge engineers
prepare a proposal for the registries describing how such101
ambiguities might be resolved and providing test cases show-
ing forecasts that illustrate the proposed resolutions. Each
registry responds in its own time-frame, based on its internal
decision-making processes. If registry interpretations differ,
IMM/Serve can incorporate two or more variations of por-
tions of the logic. As each registry clarifies its desired con-
tent, an IMM/Serve “test release” is prepared for that registry
which undergoes an iterative process of testing and refine-
ment before it is placed into operational use. If the registries’
time-frames for refinement and testing are different, then
on a given date, one registry may be using a more recent
release than another. In addition, each registry has the oppor-
tunity to initiate a content revision or customization at any
time and have that change go into effect when testing has
been completed.
In June 1999, a new version of IMM/Serve was completed
for dissemination. Since that time (through February 2001),
we have kept a log of all changes made to the knowledge
base. These changes include (1) modifications made in re-
sponse to changes in the recommendations of the ACIP and
(2) customizations of the logic requested by different IMM/
Serve users. In addition, the log contains a record of all
logic problems detected in the knowledge base subsequent
to the initial debugging process. When a change is made
to IMM/Serve’s knowledge, there is an initial process of
incremental debugging, as with any computer programming
project. Problems detected in this initial debugging process
are not included in the log. Once a modification is deemed
ready for testing by IMM/Serve’s users, any problems de-
tected subsequent to that point are logged. These logic prob-
lems include (1) errors made in encoding the specified logic
for modifications and customizations, (2) inadequacies and
gaps in the specification of that logic, and (3) unanticipated
consequences of that logic when implemented in the clini-
cal environment.
Tables 1–3 outline the national modifications, local cus-
tomizations, and logic problems contained in IMM/Serve’s
knowledge maintenance log. The remainder of this section
discusses each of these tables in turn.
3.1. Changes in Response to Major Modifications in the
National RecommendationsEach January, the Morbidity and Mortality Weekly Report
(MMWR) publishes the “Recommended Childhood Immu-
nization Schedule, United States” for the new calendar year,
a schedule that incorporates the additions and revisions ap-
proved at the previous year’s ACIP meetings. As outlined
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in Table 1, the 2000 and 2001 schedules contain several
changes with significant implications for IMM/Serve’s
knowledge base.
Simplification of the Polio Recommendations
In 2000, there was a major simplification of the polio
vaccine logic. Prior to 1999, OPV vaccine was preferred,
but either OPV or IPV vaccine could be used. In 1999, major
new complexities were introduced. (1) A new “sequential”
schedule was recommended, consisting of two IPV doses
followed by two OPV doses. (2) At the same time, the
options of using all IPV or all OPV were recommended
as acceptable alternatives. (3) In addition, an accelerated
schedule using OPV was recommended for children who
had not received a polio vaccination prior to 7 months of
age. In 2000, these recommendations were dramatically sim-
plified and only IPV was recommended for routine use (al-
though OPV doses continue to count as part of a patient’s
history).
This simplification meant that the all-OPV schedule, the
sequential schedule, and the accelerated schedule could all
be removed. One hundred forty-eight rules dealing with
the forecasting of polio were removed from IMM/Serve’s
knowledge base, and 21 rows of parameters for polio doses
were deleted from the forecasting table.
Adding and Removing New SeriesThe period 2000–2001 was unusual in that two new vac-
cine series were introduced, and one series was suspended.
Brief description Dates implemented
Polio simplification 12/99–1/00
HepA (new series activation & refinement) Early–mid 1999
SPn (new series activation & refinement) 6/99–10/00
Rotavirus (new series—inactivation) Early–mid 1999
Series activation/inactivation capability 7/99MILLER, FRAWLEY, AND SAYWARD
Adding hepatitis A, an uncomplicated two-dose series,
required 12 new rules and modest expansion of the forecast-
ing and screening tables. The schedule for SPn is much more
complex. It has a standard four-dose schedule for the new
PCV7 vaccine beginning in infancy, and several alternative
schedules with fewer doses that apply for children with late
starts or gaps in their vaccination history. Prior vaccination
with an older pneumococcal polysaccharide vaccine may
also impact the forecasting of PCV7. Thirty-four new rules
were required, as well as table expansions and additions
to code.
In all of these modifications, the most time-consuming
task was the knowledge engineering to elucidate the implica-
tions of the various schedules and to reconcile any ambigu-
ities and inconsistencies. In addition, the anticipated continu-
ing need to add and remove vaccine series prompted a more
fundamental change to IMM/Serve itself that now allows
any series to be easily activated or deactivated by a flag set
by the user. This new feature makes it easy, for example,
to turn off Rotavirus forecasting without eliminating the
underlying knowledge, and will permit Rotavirus forecasting
to be easily turned on if a safer version of the vaccine appears
in the future.
3.2. Local Customization of the Knowledge
Customizations requested by IMM/Serve’s users have
been the most frequent reason for changes made to the
software and its knowledge base. Customizations to the clini-
cal content are usually motivated by one of the following.Hepatitis A vaccination was added for routine use in states
and communities with consistently elevated rates of the dis- 1. Gaps or inconsistencies in ACIP’s recommendations
may require users to specify their own interpretation ofease. Routine vaccination against Streptococcus pneumoniae
(SPn) was added. Rotavirus vaccination, added as a new immunization rules.
2. ACIP guidelines may define ranges or alternative rec-series just 1 year earlier in 1999, was removed due to
safety concerns. ommendations from which users select their preferences.
TABLE 1
Changes of IMM/Serve’s Knowledge Required to Accommodate Major Modifications of the National RecommendationsProgramming changes
Table changes Rule changes (approx. effort)
Yes 148 rules removed None
Yes 12 new rules 25 h
Yes 34 new rules 35 h
Yes 17 new rules 25 h
No minor changes 10 h
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3. Clinical practices unique to a clinical setting may re-
quire special behaviors.
4. Particular database design and content issues at a site
may result in desired or required customizations.
Table 2 outlines the major customizations of IMM/Serve
performed during the period 6/99–2/01. In addition, we have
included certain earlier customizations that illustrate interest-
ing issues. The remainder of this section discusses each of
these customizations in turn.
Gaps and Inconsistencies in the ACIP Recommendations
This section describes specific issues that have arisen in
trying to “fill the gaps” in the national recommendations.
These issues are typically detailed, may be quite arcane, and
illustrate the complexity involved in maintaining a guideline
Accommodating missing dose numbers 2–5/98
(IHS & OHD)
Forecasting TdB in absence of primary 6/99
DTP doses (IHS)
Integrated Td variation (VA) 11/00103
users (the IHS and OHD) developed different interpretations.
Both use an 8-week wait interval when forecasting a final
dose at/after 15 months of age. When screening the previous
history, however, the IHS determined that any dose given
at/after 15 months of age should complete the series regard-
less of the interval from a preceding dose. The OHD, how-
ever, decided that a minimum 4-week interval should elapse
from any prior dose given before 15 months of age. These
differing interpretations were implemented through different
entries in each user’s screening table.
2. Hib completion variations 1 and 2. Another differ-
ence in interpretation was more complicated and required
rule and code changes. This involved the question of when
Hib dose 3 at or after 12 months of age will complete the
series when doses 1 and 2 were given prior to 12 months
of age. The OHD determined that a 4-week interval from a
prior dose before 12 months of age should complete thesuch as IMM/Serve.
series. The IHS wanted an 8-week interval.
The IHS also required a rule and code change to imple-1. Hib completion at or after 15 months of age. The
national guidelines failed to clarify all circumstances in ment a subtle interpretation in the Hib series. In their opinion,
since Hib dose 3 at/after 12 months of age completes thewhich a Hib dose received at or after 15 months of age
should complete the series, and IMM/Serve’s two primary series if it is 8 weeks after dose 2, then a dose 4 at/after 12
TABLE 2
Local Customizations to IMM/Serve’s Knowledge
Programming changes
Brief description Dates implemented Table changes Rule changes (approx. effort)
Gaps/inconsistencies
Hib completion at/after 15 months 2/00 Yes None None
Hib completion variation 1 (OHD) 3/00 No 1 rule modified 5 h
Hib completion variation 2 (IHS) 3/00 No 1 rule modified None
Date sensitive screening 8/00 Yes None 10 h
Schedule preferences
Past-due wait interval (IHS) 10–11/98 Yes None 20 h
Flexibility in balancing visits vs needle- 9/00 Yes None None
sticks (IHS)
Forecasting/screening customizations (VA) 10–11/00 Yes None None
Unique requirements
Hib PRPOMP1 variation (IHS) 12/98 No 1 rule modified 1 h
HepB 4th dose variation (IHS) 12/00–1/01 Yes 13 new rules 5 h
1 rule modified
Local database design and content considerationsNo None 500 h
No 1 new rule 10 h
5 rules
modified
Yes 6 new rules 5 h
16 rules
modified
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months of age should also complete the series if it is 8 weeks
after dose 2. That implies that the interval between doses 3
and 4 is not relevant when screening previous doses. As a
result, the IHS’s screening table contains no required mini-
mum interval between Hib doses 3 and 4.
3. Date-sensitive screening. Occasionally a new com-
ment in an ACIP footnote will have major implications
for the computer-based guideline. In 1999, a new sentence
appeared in a hepatitis B footnote indicating that infants
should receive dose 3 at least 4 months after dose 1. This
new wait interval could be readily used when forecasting
HepB 3 doses yet to be given. At first, however, IMM/
Serve’s users did not want to invalidate previous doses which
did not satisfy the new requirement. By mid 2000, users felt
that the new requirement had been in existence long enough
that it should be used in screening patients’ histories. The
challenge was to make the criterion “date-sensitive” so that
it would apply only to doses given after the recommendation
had changed. New functionality was added to IMM/Serve
through its code and table structure to allow different interval
criteria to apply to HepB dose 3 depending on the calendar
date when the dose was given. The threshold date can be
specified (as one of the parameters that defines a version of
IMM/Serve) by users based on local practice preference.
Local Schedule Preferences
Certain components of the ACIP guidelines provide lati-
tude that allows local adaptation of the recommendations.
This latitude can often be taken advantage of by using differ-
ent versions of IMM/Serve’s forecasting table. For example,
the IHS currently has nine different versions of this table.
These contain the following number of alternative sets of
parameters for the various vaccine series: DTP (2), HepA
(1), HepB (2), Hib (4), MMR (2), polio (3), SPn (1), and
Var (2). Oregon and Virginia currently each use only one
version of the forecasting table. These versions are different
from each other and from the nine IHS versions.
1. Flexibility in balancing visits vs needle-sticks (IHS).
As the number of vaccine series has increased, providers
and parents have become concerned about the number of
needle-sticks that a child receives at each visit. The ACIP
schedule allows an age range for many doses, for example:
6–18 months for HepB dose 3 and IPV dose 3, 12–15
months for MMR dose 1, and 12–18 months for Var dose
1. This allows clinics to balance the number of visits vs
the frequency of needle-sticks, for example, allowing fewer
shots at each visit but more visits. The IHS has taken advan-
tage of these ranges to define several schedules with differingMILLER, FRAWLEY, AND SAYWARD
recommended ages for various doses. For example, one IHS
schedule recommends two visits 3 months apart with three
doses at each visit (IPV dose 3, SPn dose 4, and Var dose
1 at 12 months, and DTaP dose 4, Hib dose 4, and MMR
dose 1 at 15 months). Other schedules specify different
patterns of recommended ages. Two new IHS schedules
were developed in September 2000 to increase the choice
of schedules for IHS sites.
2. Forecasting/screening customizations (VA). In late
2000, Virginia adopted IMM/Serve for use by its state regis-
try. As a new user of IMM/Serve, one of the Virginia regis-
try’s first tasks was to develop the tables of forecasting
and screening parameters. In consultation with its clinical
provider community, the registry determined, for each dose
in each vaccine series, the minimum age and intervals that
must be satisfied for a dose to be valid. It then made a
similar selection of forecasting parameters, including the
minimum acceptable age, the earliest recommended age, the
maximum age, the past due age, the past-due interval, and
the required wait interval(s) from preceding doses in its own
series and, if a live vaccine, from other live vaccine series.
3. Past-due wait interval (IHS). Registries that provide
recall and reminding functions often make an important
distinction between patients who are “due” vs those who
are “past due” for immunizations in terms of the outreach
activities that are conducted. The ACIP recommendations
do not contain explicit definitions as to when a dose is late
(past due). It is up to a user to determine how much time
after the recommended age, and/or after the previous dose
in a series, must pass before a given dose is considered past
due. In its initial design, IMM/Serve determined that a dose
is past due when the patient attains the “past-due age” for
that dose and satisfies the required wait interval from a
preceding dose. In practice, this meant that children who
started a series late were often past due for the next dose
as soon as they were eligible to receive it (as soon as the
minimum wait interval had elapsed). The IHS decided that
this was too strict a standard, and requested that a past-due
interval also be included in IMM/Serve’s forecasting table.
The IHS defines past-due intervals as longer than the re-
quired intervals. The past-due interval was implemented with
new code and forecasting table structure changes.Unique Local Requirements
Several regional IHS practices have prompted changes to
IMM/Serve.
1. Hib PRPOMP1 variation (IHS). A logic variation
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(named “PRPOMP1”) was added for IHS regions that prefer
to give PRPOMP as the first Hib dose, followed by three
HbOC doses. This variation is discussed in detail in Sec-
tion 4.1.
2. HepB fourth dose variation (IHS). A recent change
was made to accommodate the use of Comvax, a combined
Hib–HepB vaccine, at IHS sites. Their use of this combina-
tion deliberately results in an unnecessary HepB dose at 4
months of age. To accommodate this change, a customized
logic variation lowers the minimum screening age for HepB
dose 3 to 10 weeks, the same as Hib 2, and then produces
a forecast for a fourth HepB dose along with Hib dose 4 at
age 12 months or later. Previously, a HepB dose 3 would
have been screened as invalid at under 6 months of age. Since
the IHS is promoting the use of the combination vaccine, it
does not want clinicians to be told by IMM/Serve that the
HepB dose 3 was “invalid.”
Local Database Content and Design Considerations
Significant customizations have been introduced because
of database content and design issues at user registries.
1. Accommodating missing dose numbers (IHS and
OHD). The OHD and IHS registries are among the minor-
ity which store a series dose number in addition to the date
of each dose. The recording of dose numbers allows there
to be “missing doses” in a series, e.g., where HepB dose 1
and dose 3 are recorded but HepB dose 2 is not. This situation
may occur because a dose was given elsewhere and the
exact date of the dose is not known to the registry. Since a
significant fraction of children have this type of incomplete
history (10–15% within the IHS), both the OHD and the
IHS wanted IMM/Serve to produce a forecast if possible
even in the presence of missing doses. A sustained effort of
over 500 man-hours was undertaken to create several ways
of producing forecasts when histories are incomplete. This
work is described in [22].
2. Forecasting TdB in the absence of primary DTP doses
(IHS). A second example of this type of customization
accommodates people entered into the IHS database as ado-
lescents or adults, for whom the record of childhood immuni-
zations is not available. The IHS did not want the primary
DTP series doses to be forecast for people 11 years and
older if their histories contained no previous DTP doses.
Rather, they wanted the first Td booster dose to be forecast.
However, if the history contained a partial but incomplete
primary series, then the forecast should focus on completing
that primary series rather than starting Td boosters.105
3. Integrated Td variation (VA). Another customization
dealt with determining whether a Td dose functions as a
primary series dose or a booster dose. Based on the practice
at the OHD (IMM/Serve’s first registry user), a Td booster
was assigned a different code from a Td primary dose, and
forecasting and screening were based on the code. However,
it is the practice in many registries, including Virginia’s, that
a Td always has the same code (e.g., HL7 vaccine code
9) independent of how it is used. To accommodate this
requirement, we added a capability to IMM/Serve to inspect
all DTP series doses in a child’s history to determine whether
and how the dose contributes to primary and booster series.
This required rule, table, and code changes to IMM/Serve.
3.3. Logic Problems Identified in the Knowledge
Table 3 outlines the major logic problems identified in
IMM/Serve in the period 6/99–2/01. This section discusses
those problems in turn.
1. Incomplete history logic problem. In the MMR se-
ries, there was previously no minimum age listed in IMM/
Serve’s forecasting table for the second (final) dose, just a
minimum wait interval from the first dose. This caused no
problems when IMM/Serve was used with complete immu-
nization histories. It had been deliberately left out because
it was not needed. Once we implemented the incomplete
history capability described above, however, IMM/Serve
was not able to accommodate an MMR dose 2 following a
missing MMR dose 1 since the minimum age for dose 2
was not specified. This problem was readily corrected by
explicitly listing in the forecasting table the (previously im-
plicit) minimum age for MMR dose 2 (the minimum age
for dose 1 plus the minimum wait interval to dose 2). This
is an interesting problem because it illustrates that even if
a KB is complete and correct, it may turn out to be inadequate
when a new capability is added.
2. Incomplete formulation of the Hib PRPOMP1 customi-
zation. As described previously, two IHS schedules use a
variant of the Hib forecasting logic where the PRPOMP
brand is given for dose 1 and HbOC is given for the subse-
quent three Hib doses. In formulating this customization,
we all neglected to anticipate that if two PRPOMP doses
had already been given (for doses 1 and 2), then the clinics
would want to complete the series with a single PRPOMP
for dose 3. The customized version of IMM/Serve’s logic
was forecasting HbOC in this circumstance as had been
customization
HepB dose 1 maximum age problem 6/99 No 1 rule modified None
No 2 new rules, NoneUnanticipated implications of Hib logic 3/00
Inconsistent polio completeness and forecasting 6/00
rules
Date sensitive series completion logic for the HepB 1/01
dose 4 variation
implicitly requested. This problem was corrected by modi-
fying one rule. This problem is discussed in more detail in
Section 4.1.
3. HepB dose 1 maximum age problem. HepB dose 1
is unique in that it is frequently given on the day of birth,
and therefore does not have a minimum age. As a result,
IMM/Serve’s original rule-based logic did not check the
tabular parameters for the minimum age for this dose. Unfor-
tunately, this inadvertently meant that IMM/Serve also did
not check for the dose’s maximum age either, which is
part of the tabular knowledge. As a result, IMM/Serve was
forecasting HepB dose 1 for patients over the age of 18
years who had not had previous HepB vaccinations. (This
is consistent with the national guidelines, but not with IHS
practice.) This problem was not identified until beta testing
because IMM/Serve is really designed for use with younger
children. This error was corrected by including a check of
the tabular parameters for HepB dose 1, making it consistent
with all the other vaccine series doses. This problem illus-
trates the need to check a guideline’s logic at the edges of
its envisioned scope. This error only occurred in patients
older than those whom IMM/Serve is really designed to
serve.
4. Unanticipated implications of Hib logic. In the proc-
ess of testing the Hib completion variants selected by the
IHS, IMM/Serve’s knowledge engineers discovered an
anomaly in the logic implied by published recommendations
for Hib. The recommendations have unusual and presumably
unanticipated clinical consequences, as discussed in detail
in Section 4.2.
5. Inconsistency in polio completeness and forecasting
rules. When IMM/Serve’s rules and tables dealing with2 rules modified
No 1 new rule, None
1 rule modified
No None 10 h
polio forecasting were revised for the 2000 all-IPV schedule,
we oversimplified the forecasting rules for dose 4 of polio.
The rewritten rule for indicating that IPV 3 is due on the
forecast date also stated that IPV 4 would be due next.
However, in certain circumstances, an IPV 4 is not required,
namely, when IPV 3 is at/after 4 years and OPV was not
one of the prior polio doses; in this case, the IPV 3 completes
the series. This logic had been included in the previous
version of the polio rules, which had been much more com-
plex. Once this error had been identified by OHD testing,
correction involved one rule modification and one new rule.
This is an example of an inadvertent error made in revising
the logic.
6. Date-sensitive series completion logic for the HepB
dose 4 variation. As described previously, at the end of
2000 we implemented a “HepB fourth dose” logic variation
for the IHS. In this variation, a valid dose 3 no longer
automatically completes the series; the series-completing
dose 3 must be at/after 6 months of age and a 4-month
interval from dose 1, whereas a valid dose 3 could now be
as early as 10 weeks of age and 8 weeks from dose 1. We
did not anticipate the problem this caused for patients who
in the 1990s had three HepB doses when the rules allowed
a HepB 3 at 4 or 5 months of age, and 12 weeks after dose106 MILLER, FRAWLEY, AND SAYWARD
TABLE 3
Logic Problems in the IMM/Serve Knowledge Maintenance Log
Programming changes
Brief description Dates implemented Table changes Rule changes (approx. effort)
Incomplete history logic problem Mid 1999 Yes None None
Incomplete formulation of Hib PRPOMP1 Mid 1999 No 1 rule modified None1, to complete the series. IHS testers discovered that such
patients, who had formerly been considered complete, were
now being forecast for a fourth HepB. The solution was to
allow the older completeness rule to apply to HepB 3’s given
before a certain date, and the newer rule to apply to HepB
3’s given at/after that date. This required changes to rules,
code, and table functions in IMM/Serve.
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4. DOMAIN KNOWLEDGE REQUIRED FOR
INCREMENTAL VALIDATION: USING
KNOWLEDGE INTERNAL VERSUS EXTERNAL
TO THE IMPLEMENTATION LOGIC
This section discusses logic problems recorded in IMM/
Serve’s knowledge maintenance log (described above) from
the perspective of the type of knowledge that could be used
to identify such problems in an automated fashion. There
are several general approaches that might be used to drive
this testing process. These include:
Testing the implementation logic directly. One approach
involves using tools that operate directly on the knowledge
base and help test for inconsistency and redundancy.
Generating test cases based on the implementation
logic. A second approach involves developing tools that
systematically generate combinations of clinical input con-
ditions to the guideline. These combinations can be used
to create sets of test cases that help test the guideline’s
operation.
Using domain knowledge external to the implementation
logic. A third approach involves developing tools that use
domain knowledge not contained within the computer-based
logic itself. When the implementation logic of a guideline
is encoded in the computer, that logic is based on a broad
understanding of many domain issues. This broader domain
knowledge is essentially “distilled” into the more focused
logic that is actually encoded in the machine. In the process,
much of the broader knowledge typically gets “left behind.”
It is reasonable to expect that portions of this broader domain
knowledge need to be placed into computer-based form to
allow certain types of errors to be detected in an auto-
mated fashion.
In this section, we refer to approaches 1 and 2 as using
domain knowledge that is internal to the implementation
logic, and approach 3 as using domain knowledge that is
external to that logic.
As described under Background, we have developed sev-
eral computer-based tools to assist in the process of validat-
ing IMM/Serve’s knowledge. These include IMM/Def [18],
IMM/Test [19], and T/Gen [21]. We have been using these
tools to help test new versions of IMM/Serve, in addition
to testing the logic with hand-crafted sets of test cases. These
tools fall largely into categories 1 and 2 above, in that they
employ knowledge internal to IMM/Serve’s knowledge base
(KB), combined with a human tester’s knowledge of the
domain. We are particularly interested in exploring what107
type of knowledge external to IMM/Serve’s KB might also
be used to help in the automated testing of IMM/Serve.
This section discusses these issues, focusing on two of
the logic problems discussed in the previous section. For
each of the two logic problems, we discuss in turn (1) the
nature of the problem, (2) how the problem can be corrected,
(3) how the problem might be automatically detected, and
(4) the type of domain knowledge required to identify
that problem.
4.1. Logic to Support a Customized Use of Hib Brands
The Problem
There are two different brands of Hib vaccine, HbOC and
PRPOMP, forecast by IMM/Serve. The guideline recom-
mends that a child should receive all of one brand or all of
the other. It takes four doses to complete the series using
HbOC and three doses using PRPOMP. When using the
three-dose PRPOMP schedule, the minimum interval be-
tween doses 2 and 3 is twice as long as when using the four-
dose HbOC schedule. If a child has already received both
brands (a “mixed series”), then all doses are treated as if
they were HbOC and the four-dose schedule is used.
As described previously, one customization requested by
the IHS was to create a special schedule using PRPOMP
for dose 1 and HbOC for doses 2–4. This logic was incorpo-
rated into IMM/Serve’s rule-based knowledge as a rule varia-
tion. When clinicians started testing the logic, however, they
discovered that if a child had already received two PRPOMP
doses, the new variation of IMM/Serve was forecasting doses
3 and 4 to be HbOC. On reflection, in this circumstance the
clinicians wanted the series to be completed by a third (and
final) dose of PRPOMP. Thus, the logic for the customization
had not been fully thought through when it was first defined
by the IHS.
Correcting the Problem
A modification to a single IMM/Serve rule was able to
produce the desired behavior.Logic Required to Identify the Problem Automatically
There are a variety of ways in which one might attempt
to identify this potential problem automatically. We imple-
mented a pilot solution (using the LISP programming lan-
guage) which is illustrated schematically in Fig. 1. Figure
FIG. 1. A transition network outlining alternative schedules for
Haemophilus influenzae type b (Hib) vaccine. Each node (circled letter)
represents a dose decision point. Each arc corresponds to the administra-
tion of a Hib vaccine brand (HbOC or PRPOMP). Numeric subscripts
refer to three different approaches for administering Hib vaccine (un-
numbered arcs represented possible, although unrecommended, op-
tions). An automated process (described in the text) has identified
two nodes, C and D (labeled with “?”), which have exit paths under
approaches 1 or 2, but no exit path under approach 3.
1 shows a transition network that outlines the various alterna-
tive Hib schedules. Each arc is labeled with one brand of
vaccine: HbOC or PRPOMP. The arcs labeled 1 and 2 corre-
spond to the two standard approaches: all PRPOMP (the
arcs labeled 1) and all HbOC (the arcs labeled 2). The
arcs labeled 3 outline the IHS PRPOMP1 variation: one
PRPOMP followed by three HbOC. The unnumbered arcs
correspond to nonrecommended doses that a child might
nevertheless receive. If the knowledge of Hib is structured in
this fashion, then a computer program can operate as follows:
1. Look at each node (i.e., each dose decision point).
2. If a node has an exit arc that corresponds to variation
3, then go on to the next node.
3. If the node has no exit arc that corresponds to the new
variation (3), but has an exit arc that corresponds to an
established variation (1 or 2), then flag that node for exami-
nation.
This logic results in nodes C and D being flagged for
examination (indicated by “?” in Fig. 1). Based on this logic,
the program can ask the design team explicitly:1. Concerning node C: If a child has previously received
two PRPOMP doses, what do you want to do?
2. Concerning node D: If a child has previously received
one HbOC dose, what do you want to do?
This would force the clinicians to think explicitly about
two circumstances they may not have considered.MILLER, FRAWLEY, AND SAYWARD
Characterizing the Domain Knowledge Used
The domain knowledge used to help identify this error
involves knowledge about clinical practice customs, prefer-
ences, and expectations. It reflects the fact that the existence
of other standard practice preferences may affect the newly
added approach if a deviation from that approach has oc-
curred.
4.2. Anomalous Logic for Hib Dose 3
The Problem
A curious problem occurs with the latest version of the
IHS Hib logic.
1. Hib is normally a four-dose schedule, all given before
age 16 months.
2. If dose 3 is given before 12 months of age, then (a) a
wait interval of 4 weeks from dose 2 is required, and (b) a
fourth Hib dose will be scheduled.
3. If dose 3 is given at or after 12 months of age, however,
then (a) a wait interval of 8 weeks from dose 2 is required,
and (b) no further Hib doses are recommended.
4. IMM/Serve’s logic initially indicated that if (a) the
patient’s age was less than 12 months, (b) dose 2 had been
given, and (c) dose 3 was not yet due, then schedule dose
3 four weeks after dose 2. One problem was that if the
patient received dose 2 after 11 months of age and returned
one month later, he would be over 12 months of age and
dose 3 would not be due until 8 weeks after dose 2.
Correcting the Problem
This is an example of a very quirky set of decision rules
whose consequences had (presumably) not been anticipated
when they were developed. For example, a curious situation
occurs if dose 2 is given between 10 and 11 months of age.
In this situation, IMM/Serve can schedule the child to return
4 weeks after dose 2 for dose 3. If, however, the child returns
a little late (e.g., just after turning 12 months old), then dose1083 will “suddenly” not be due, and the child will need to
wait until 8 weeks after dose 2.
There is no clear-cut solution to this problem. The most
reasonable approach is to explain the problem to local clini-
cal experts and come to a consensus as to how IMM/Serve
should handle the various scenarios that arise. (The solution
actually developed in consultation with local experts was to
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change the logic so that there was a 8-week interval between
dose 2 and dose 3 if dose 2 is given at over 10 months of age.)
Logic Required to Identify the Problem Automatically
To demonstrate how this type of problem might be identi-
fied automatically, we wrote a LISP program that examines
IMM/Serve’s tabular and rule-based logic to identify the
following circumstance:
1. there are two sets of parameters that apply to a dose,
2. the two sets of parameters correspond to different mini-
mum ages (i.e., one earlier than the other) but in all other
respects may apply to the same patient, and
3. the wait interval (from the previous dose) associated
with the earlier minimum age is shorter than that associated
with the later minimum age.
If this circumstance is identified, the program can alert
the design team as to the possibly unintended clinical impli-
cations of the recommendations.
Characterizing the Domain Knowledge Used
The domain knowledge used to help identify this error
involves knowledge about the temporal relationships and
temporal constraints involved in childhood immunization.
The knowledge used to identify these errors is not encoded
in IMM/Serve’s current knowledge base of rules and tables.
It exists in the heads of the development team. If some more
sophisticated formalism was used to represent IMM/Serve’s
knowledge base (for example, a formalism that represented
temporal constraints and sequences of practice preferences),
perhaps this knowledge could be encoded. In the future, as
we identify additional errors that may be introduced into
IMM/Serve, we will explore whether additional types of
domain knowledge external to the current implementation
logic might be useful in identifying those errors, and whether
more general tools or formalisms might be developed to
assist in maintaining computer-based immunization logic
based on that knowledge.5. DISCUSSION
This section discusses some of the issues that arose in the
course of this project.109
5.1. Using Underlying Immunization Domain
Knowledge to Help Detect Logic Problems
It is widely recognized that the knowledge encoded in
the computer-based logic of a clinical guideline represents
only a portion of the clinical knowledge upon which the
guideline is based. For example, in the domain of childhood
immunization, the ACIP creates its guidelines based on a
variety of fundamental knowledge about the domain, in-
cluding:
1. knowledge about the actions, interactions, and adverse
side effects of the vaccines based on a broad range of scien-
tific and epidemiological studies,
2. knowledge about the vaccine scheduling process, in-
cluding the potentially competing goals of trying to (a) max-
imize immunity, (b) keep the vaccination schedule as simple
as possible, (c) minimize the number of required clinic visits
to the extent possible, and (d) minimize the number of nee-
dle-sticks a child must receive at a single visit and in total.
It is interesting that this type of fundamental knowledge
about immunization is not the type of external domain
knowledge identified above that might help drive the valida-
tion of IMM/Serve. Rather, the type of external domain
knowledge identified as useful involves:
1. knowledge about practice customs, preferences and
expectations, and
2. certain types of temporal knowledge about the immuni-
zation process.
As we continue to use IMM/Serve’s knowledge mainte-
nance log, we may well identify further types of domain
knowledge that could be used to automatically drive the
process of knowledge validation. We believe that it is im-
portant to keep a detailed log of actual changes to the guide-
line knowledge and of the actual problems (errors, inadequa-
cies, and unanticipated implications) that arise in response
to these changes to most effectively explore these issues.
5.2. A Range of Computer-Based Validation Tools and
StrategiesAs discussed throughout this paper, there is range of differ-
ent computer-based tools that can help in the testing and
validation of a computer-based guideline. One way to charac-
terize these tools is based on the type of knowledge used
to drive their operation.
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hood immunization. Other domains will undoubtedly pose
additional challenges and expose different types of domain110
1. A tool can be developed to focus specifically on analyz-
ing the computer-based logic itself, for example, trying to
identify inconsistencies, redundancies, and incompleteness.
Such a tool would not need to contain any knowledge about
the clinical domain, just about the knowledge representation
used. This knowledge representation would need to be con-
strained in its expressiveness. Examples include tables and
if–then rules. If the knowledge is expressed in procedural
program code, a validation tool would not be able operate
in a comprehensive fashion, since the correct behavior of
an arbitrary computer program is inherently unprovable.
2. A tool can be constructed to generate automatically
sets of test cases that involve different combinations of the
clinical conditions contained in the implementation logic.
These test cases can then be used to test the operation of
the system as a whole. Here, one is not just testing the logic,
but the entire system that implements the logic. As a result,
this approach could achieve more complete testing, at least
of certain features of the system, than just testing the clinical
logic itself.
For a complex guideline, however, the total number of
combinations of clinical conditions may be so very large
(e.g., millions) that they cannot be tested exhaustively. One
way to deal with this problem is to test selected features of
the logic with focused sets of test cases, each set generated
from a limited set of clinical conditions. Another comple-
mentary approach is to constrain the number of test cases
generated using some kind of semantic model of the domain.
A clinical example of this approach is described in [21]. This
approach may involve using additional domain knowledge
external to the implementation logic. Here, however, the
additional domain knowledge is only used to make the test-
ing (using combinations of clinical conditions from the im-
plementation logic) more efficient, not to test aspects of the
system not contained in that logic.
3. The third type of tool uses knowledge of the domain
external to the implementation logic to test features of the
system not explicitly encoded in that logic. In this paper,
we have described two examples of the type of problem
such knowledge might be used to help identify.
5.3. The Potential Utility of Graphically Driven ToolsAs illustrated in Fig. 1, certain domain knowledge useful
to drive validation in this domain lends itself to graphical
visualization. Indeed, in a previous project, we explored a
graphical paradigm for expressing immunization logic to
help the knowledge engineering team in understanding anddiscussing the details of that logic [23]. This experience
suggests that graphically driven tools might be useful to
help drive the validation of computer-based immunization
guidelines.
6. SUMMARY
It is widely acknowledged that many, if not most clinical
practice guidelines evolve significantly over time and require
local customization, and that these issues pose major chal-
lenges for the development of operational computer-based
guidelines. A good way to fully understand the complexity
of these problems is to keep a detailed log of the changes
made to a computer-based guideline and of the problems
that are introduced in the process of making these changes.
A key issue concerns how best to validate each new version
of the guideline, including the detection and correction of any
errors. Software tools will be essential to allow expeditious
validation. To develop such tools, we need to understand
the nature of the domain knowledge required to perform as
comprehensive an automated validation as possible.
This paper explores these issues in the domain of child-knowledge required to assist in automated validation. The
present project is one step in exploring these issues, which
will become increasingly important as more and more com-
plex computer-based clinical guidelines become operational
and need to be maintained on a continuing basis.ACKNOWLEDGMENTS
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